Previous studies have suggested that IDH1 mutations, P53 mutations, MGMT promoter methylation, and ATRX loss indicated a good therapy response and longer OS in high-grade glioma (41, 43, 44). The gene discussed is MGMT; the disease is central nervous system cancer.